The Science Of
HBV Cure
Meeting 2024

26 to 27 July 2024

8:30 am to 5:00 pm (SGT)

The Science Of Hbv Cure Meeting 2024

26 to 27 July 2024

8.30 am to 5.00 pm (SGT)

The format (Live or Online) of the Science of HBV Cure Meeting 2024 will be confirmed by the end of March 2024.

MEET SOME OF OUR EXPERTS

The Science of HBV Cure Meeting 2024 Scientific Programme.

July, 2024

26

Programme Time (SGT)
Welcome Remarks by the Conference Chairman 10:00 – 10:05
Opening Symposium: Overview of HBV Functional Cure
Moderators: Prof. Pietro Lampertico, Prof. Seng Gee Lim
HBV Cure: definitions and prospects
Prof. Pietro Lampertico, Italy
10:05 – 10:25
The Role of ICE-HBV in HBV functional cure
Prof. Massimo Levrero, France
10:25 – 10:45
Are HBV flares necessary for functional cure?
Prof. Kumar Visvanathan, Australia
10:45 – 11:05
Virological Insights into functional cure
Moderators: Thomas Tu, Dr. Jayantha Gunaratne
Is cccDNA silenced or lost in functional cure?
Prof. Massimo Levrero, France
11:05 – 11:25
Removing integrated HBV
Dr. Thomas Tu, Australia
11:25 – 11:45
New virological targets leading to functional cure
Prof. Pei Jer Chen, Taiwan
11:45– 12:05
Free Paper: The role of HBx in functional cure
Dr. Aravind Sivakumar, Singapore
12:05 – 12:20
Free paper: BMP pathway is a target for functional cure
Dr. Jayantha Gunaratne
12:20 – 12:35
Free paper: HBV functional cure is related to baseline qHBsAg and interferon response
Prof. Seng Gee Lim, Singapore
12:35 – 12:50
Lunch 12:50 – 13:45
Immunological insights into functional cure 
Moderator: Dr. Valerie Chew
What we have learnt from interrogating the liver microenvironment : A review
Dr. Ram DasGupta, Singapore
13:45– 14:05
Understanding the immune mechanisms to achieve functional cure
Prof. Eui-Cheol Shin, Korea
14:05– 14:25
Free Paper Presentations
Free paper: The Role of STING Signaling Pathway in Chronic Hepatitis B: Implications for Immune Status
 Dr. Zhang Mingyuan
14:25 – 14:40
Animal Models  
Moderator: Prof. Eui-Cheol Shin, Massimo Levrero
A humanized animal model with matching immune system
Dr. Qingfeng Chen, Singapore
14:40 – 15:00
Animal model forum: How to use animal models in HBV drug development
Prof. Pei-Jer Chen, Dr. Qingfeng Chen, Dr. Guofeng Cheng, Dr. Zhi Hong
15:00 – 15:15
Capsid Assemby Modulators
Moderator: Prof. Harry Janssen
The role of Capsid Assembly Modulators in functional cure
Prof. Man Fung Yuen, Hong Kong
15:15 – 15:35
Invited Pharma Presentations
Moderator: Prof. Harry Janssen
Preclinical Profiling of ABI-6250, a Novel Orally Bioavailable Small-Molecule Therapeutic Candidate for the Treatment of Chronic Hepatitis (Virtual)
Dr. Marc Windisch, Assembly
15:35 – 15:55
Aligos Assets for HBV functional cure
Dr. Min Wu, Aligos
15:55 – 16:10
Tea Break 16:10 – 16:30
Biomarkers
Moderator: Prof. Seng Gee Lim
Biomarkers for functional cure
Prof. Man-Fung Yuen, Hong Kong
16:30 – 16:50
Free paper: progress in biomarker discovery for HBV functional cure
Dr. Zijie Lim, Singapore
16:50 – 17:05
Invited Pharma Presentations
The performance and clinical utility of novel highly sensitive iTACT-HBsAg and iTACT-HBcrAg assays
Dr. Kazuyoshi Miyamoto, Fujirebio
17:05 – 17:20
Your partner in HBV management (Virtual)
Dr. Mark Anderson, Abbott Diagnostics
17:20 – 17:35
Closing remarks 17:35 – 17:45
End of day 1

July, 2024

27

Programme Time (SGT)
Special Lecture
Moderators: Dr.Thomas Tu, Prof. Massimo Levrero
Gene Editing for complete cure: state of the art
Prof. Kosh Agarwal, United Kingdom
08:45 – 09:15
RNA interference
Moderators: Dr. Thomas Tu, Prof. Massimo Levrero
Anti-sense vs siRNA: can we explain the efficacy differences?
Prof. Pei-Jer Chen, Taiwan
09:15– 09:40
Invited Pharma Presentations
Moderators: Dr. Thomas Tu, Prof. Massimo Levrero
Roche strategy for functional cure
Dr. Farouk Chughlay, Roche
09:40 – 09:55
Bepirovirsen immune mechanism of action may potentiate infected hepatocyte killing: Indirect evidence from B-together peripheral longitudinal biomarker analysis
Dr. Shilpy Joshi, GSK
09:55 – 10:10
AHB-137, a novel ASO for HBV Cure
Dr. Guofeng Cheng, Ausperbio Therapeutics Inc
10:10 – 10:25
Update on Nucleic Acid Polymers (Virtual)
Dr. Andrew Vaillant, Replicor
10:25 – 10:40
Tea Break 10:40 – 11:00
Delta Cure
Moderator: Prof. Lim Seng Gee
Path to Delta Cure
Prof. Heiner Wedemeyer, Germany
11:00 – 11:20
The role of NAPs in Delta Therapy (Virtual)
Dr. Andrew Valliant, Replicor
11:20 – 11:35
Immunology
Chair and moderator:  Dr. Valerie Chew
Insights into HBV Cure from studies of novel immune modulators (Virtual)
Prof. Antonio Bertoletti, Singapore
11:35 – 11:55
Free paper: The differentiation of Treg and Th17 cells in patients with chronic hepatitis B in different stages
Dr. Le Thi Thuy Hang, Vietnam
11:55– 12:10
Lunch 12:10– 14:00
Invited pharma Presentations
Moderators: Prof. Kumar Visvanathan
Characterisation of Selgantolimod (TLR8 agonist) against CHB (Virtual)
Dr. Frida Abramov, Gilead Sciences
14:00 – 14:15
Clonal amplification of peripheral CD8+ T cells is associated with clinical response to checkpoint blockade in chronic hepatitis B (Virtual)
Dr. Jeff Wallin, Gilead Sciences
14:15 – 14:30
Insights into CHB functional cure from Ascletis studies (Virtual)
Dr. Jinzi J. Wu, Founder, Chairman and CEO, Ascletis
14:30 – 14:45
Achieving breakthroughs in HBV Cure
Dr. Zhi Hong, Brii Bio
14:45 – 15:00
siRNA+Neutralizing antibody combination for HBV Cure
Dr. Wang Dong, Hepa Thera
15:00 – 15:15
The potential role for a novel class, a Checkpoint Modifier, in the functional cure of CHB: the science and clinical data from VRON-0200 (Virtual)
Dr. Sue Currie, Dr. Andrew Luber, Virion Therapeutics
15:15 – 15:30
Tea Break 15:30 – 15:45
Treatment strategies
Moderators: Prof. Heiner Wedemeyer
Potential of immune based therapies for functional cure: success and limitations
Prof. Tatsuya Kanto, Japan
15:45 – 16:05
The return of interferon in functional cure strategies – a step backwards?
Prof. Harry Janssen, Holland
16:05 – 16:25
Combination Therapy Forum
Moderators: Prof. Seng Gee Lim, Prof. Heiner Wedemeyer
Immunotherapy and antiviral therapy forum
Prof. Eui Choel Shin, Prof. Massimo Levrero, Dr. Thomas Tu, Prof. Harry Janssen, Prof. Pei-Jer Chen, Prof. Kumar Visvanathan, Dr. Zhi Hong, Dr. Melanie Paff, Dr. Guofeng Cheng

16:25 – 17:25
Closing remarks from Chairman 17:25 – 17:30